Business Context and Reporting Period
Company: enGene Holdings Inc. (formerly enGene Inc. post-Reverse Recapitalization with FEAC)
Reporting Period: Quarterly period ended July 31, 2024 (Q3 2024)
Business Overview: enGene is a clinical-stage biotechnology company developing non-viral genetic medicines using its proprietary DDX gene delivery platform. The lead product candidate is detalimogene voraplasmid (detalimogene) for the treatment of non-muscle invasive bladder cancer (NMIBC). The company has no commercial revenue and relies on financing to fund operations.
Key Financial Metrics
| Metric | Three Months Ended July 31, 2024 | Nine Months Ended July 31, 2024 | As of July 31, 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $14.1 million | $39.8 million | N/A |
| Operating Expenses | $16.8 million | $44.8 million | N/A |
| Cash and Cash Equivalents | N/A | N/A | $257.7 million |
| Debt (Notes Payable, net) | N/A | N/A | $22.9 million |
| Shareholders' Equity | N/A | N/A | $230.3 million |
Operating Expenses Breakdown (Nine Months 2024): Research and Development ($27.0 million); General and Administrative ($17.8 million).
Cash Flow (Nine Months 2024): Net cash used in operating activities was $28.7 million. Net cash provided by financing activities was $205.6 million, primarily driven by a $200 million PIPE financing and $22.5 million from a term loan.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss for the nine months ended July 31, 2024, increased to $39.8 million from $17.4 million in the prior year period. This is primarily due to increased R&D spending to advance the Phase 2 LEGEND study and higher G&A costs associated with operating as a public company.
- Significant Liquidity Improvement: Cash and cash equivalents increased from $81.5 million at October 31, 2023, to $257.7 million at July 31, 2024. This follows a $200 million PIPE financing completed in February 2024.
- Debt Restructuring: The company entered into an Amended Loan and Security Agreement with Hercules Capital in December 2023, refinancing prior debt. As of July 31, 2024, the company had borrowed $22.5 million under this new facility.
- Elimination of Derivative Liabilities: Unlike the prior year, the current period does not include significant changes in fair value of warrant liabilities or convertible debenture embedded derivatives, as these instruments were settled or reclassified to equity upon the Reverse Recapitalization in October 2023.
Guidance, Outlook, and Risks
Outlook and Guidance:
- Clinical Trials: The company plans to expand the Phase 2 LEGEND study to include a third cohort targeting high-risk BCG-unresponsive papillary-only NMIBC patients, with enrollment expected to begin in Q4 2024. Enrollment in the second cohort was temporarily paused for modification.
- Regulatory Timeline: Management expects to file a Biologics License Application (BLA) with the FDA mid-2026 for detalimogene.
- Liquidity: Management believes existing cash of $257.7 million is sufficient to fund operations and debt obligations for at least the next 12 months.
Management Commentary:
- Leadership Transition: Former CEO Jason Hanson resigned effective July 19, 2024. Ronald H. W. Cooper was appointed CEO on July 20, 2024. Dr. Raj Pruthi was promoted to Chief Medical Officer.
- Strategic Focus: The company deprioritized pre-clinical development of EG-i08 for cystic fibrosis to focus resources on bladder cancer indications.
Risks and Contingencies:
- Going Concern: While the material uncertainty regarding going concern was removed following the 2024 PIPE financing, the company expects to continue incurring losses and requires substantial additional funding for future operations.
- Internal Controls: The company disclosed material weaknesses in internal control over financial reporting as of July 31, 2024, related to lack of formal policies, insufficient personnel, and IT controls. Remediation efforts are underway.
- Market Risk: Exposure to interest rate fluctuations on variable-rate debt and foreign currency exchange risk (CAD/USD).
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $257.7 million cash balance against the projected burn rate, considering the increased R&D spend for the expanded LEGEND study.
- Debt Covenants: Review the terms of the Amended Loan Agreement with Hercules Capital, specifically the "Interim Milestone" requirements needed to access additional tranches of up to $7.5 million.
- Internal Control Remediation: Monitor progress on remediation of the disclosed material weaknesses in internal controls over financial reporting.
- Clinical Enrollment: Track the resumption of enrollment in the LEGEND study's second cohort and the initiation of the third cohort in Q4 2024.
- Leadership Stability: Assess the impact of the recent CEO and CMO transitions on strategic execution and operational continuity.